CME Group Inc.

NASDAQ:CME

Financial - Data & Stock Exchanges

Financial Services
$311.56 -2.39%

-$6.03 today

Market cap
$111.52B
Beta
0.24
P/E (TTM)
20.9
EPS (TTM)
$11.81
Dividend yield
4.56%
52W Low $244.56High $329.16

Volume 1.73M

Average 2.82M

CME Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

CME Group Inc.NASDAQ: CME

Research & Development · Q3 FY2026 · quarter ended Sep 2026

Research & development remains negative

Q3 FY2026 research & development was $0, compared with $0 a year earlier. Trailing-twelve-month research & development was $0.

Context

  • Research & development amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
  • Research & development increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly research & development holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMSep 2026
$0— YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
—

Research & Development vs competitors

How CME compares with its peers on the latest reported figures

  • CME's LTM Sep 2026 research & development of $0 is the highest of the 4 companies compared; the peer median is $0.
  • Research & development amounts to 0.0% of revenue for CME, versus a peer median of 0.0%.
CME Competitors Peer median
Research & Development for CME and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CMECME Group Inc.LTM Sep 2026$0 ——0.0%
ICEIntercontinental Exchange, Inc.LTM Jun 2026$0 ——0.0%
NDAQNasdaq, Inc.LTM Sep 2026$0 ——0.0%
TWTradeweb Markets Inc.LTM Jun 2026$0 -100.0%—0.0%
Peer median (excluding CME) $0-100.0%—0.0%

Competitors are the stored peer set for CME. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue4.69B5.02B5.58B6.13B6.52B
Cost of Revenue837M753.1M828.6M850.3M907M
Gross Profit3.85B4.27B4.75B5.28B5.61B
Gross Margin82.2%85.0%85.1%86.1%86.1%
Research & Development00000
Selling, General & Admin151.7M137.4M144.4M132.7M150.5M
Operating Expenses1.21B1.25B1.31B1.35B1.38B
Depreciation & Amortization385.4M362.6M352.6M336.8M330.9M
EBITDA3.93B4.02B4.67B5.04B5.78B
EBITDA Margin83.7%80.0%83.6%82.2%88.6%
Operating Income2.65B3.02B3.44B3.93B4.23B
Operating Margin56.4%60.1%61.6%64.1%64.9%
Interest Income00000
Interest Expense166.9M162.7M159.4M160.9M129.7M
Other Income / Expenses728.4M474.4M717.9M609.9M1.1B
Income Before Tax3.37B3.49B4.15B4.54B5.33B
Pre-Tax Margin71.9%69.5%74.5%74.1%81.7%
Income Tax Expense736.7M799.3M927.4M1.02B1.27B
Net Income2.64B2.69B3.23B3.53B4.04B
Net Margin56.2%53.6%57.8%57.5%62.0%
EPS (Basic)7.307.418.879.6911.18
EPS (Diluted)7.297.408.869.6711.16
Weighted Avg Shares358.34M358.71M359.02M359.39M359.63M
Weighted Avg Shares (Diluted)358.93M359.18M359.5M359.94M360.23M

CME Group Inc.

NASDAQ:CME

Intrinsic Alpha fair value

Locked

Current Price

$311.56

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.